个人简介
致力于药物设计新方法开发及应用研究，针对糖尿病、新冠肺炎等，成功发现若干新型强效的候选药物：开发目前国际上最大的疾病—靶标知识图谱可视化平台，包含超过1.7万种疾病与大于2万种基因/蛋白质之间3亿多条潜在关系，促进新治疗领域或新靶点的原创新药研发；发展AI药物代谢位点及代谢产物预测等新方法5套，已为国内外用户完成科学计算1000余次；应用上述方法开展原创新药发现研究，现已有3个候选药物完成技术成果转化。在Protein & Cell, Briefings Bioinf., J. Med. Chem.等发表SCI论文50余篇；申请发明专利17项，国内外授权12项，获软件版权3项；主持国家、省部级科研项目6项，包括国家自然科学基金面上和青年项目、国家重点研发计划子课题、临港实验室“求索杰出青年计划”、上海市“扬帆”计划和中国博士后科学基金面上一等资助。
教育背景
2011-09至2016-06，华东理工大学，药学，博士（导师：李洪林教授）
2007-09至2011-06，华东理工大学，制药工程，学士
科研与学术工作经历
2023至今，华东师范大学，人工智能新药创智中心，研究员
2019-08至2022-12，华东理工大学，药学院，副教授
2018-11至2019-07，华东理工大学，药学院，特聘副研究员
2016-07至2018-10，华东理工大学，博士后（合作导师：徐玉芳教授）
获奖及荣誉
第十五届中国药学会青年药学论坛优秀论文一等奖（2020）
第二十二届工博会高校展区特等奖（2020）
上海市青年科技英才“扬帆”计划（2018）
上海市高等学校优秀博士毕业生（2016）
第十二届“挑战杯”全国二等奖（2011）
近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Ziyan Feng, Zihao Shen, Honglin Li, Shiliang Li*. e-TSN: an interactive visual exploration platform for target-disease knowledge mapping from literature. Briefings Bioinf., 2022. 23(6) : bbac465.
Rui Xiong#, Leike Zhang#, Shiliang Li#, Yuan Sun, Minyi Ding, Yong Wang, YongliangZhao,YanWu,WeijuanShang,XiamingJiang,JiweiShan,ZihaoShen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillete, Zhenjiang Zhao,RuiWang, LiliZhu,GengfuXiao,KeLan,HonglinLi*,KeXu*.Noveland potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA virusesincludingnewly-emergedcoronavirusSARS-CoV-2. Protein&Cell,2020. 11: 723–739. （封面文章）
Fanxun Zeng#, Shiliang Li#, Guantian Yang#, Yating Luo#, Tiantian Qi, Yingfan Liang, Tingyuan Yang, Letian Zhang, Rui Wang*, Lili Zhu*, Honglin Li*, Xiaoyong Xu*. Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenaseforthetreatmentofrheumatoidarthritis.ActaPharm.Sin.B.2021. 11(3): 795-809.（封面文章）
Shiliang Li#, Chun Qin#, Shichao Cu#, Hongling Xu, Fangshu Wu, Jiawei Wang, MingboSu,XiaoyuFang,DanLi,QianJiao,MingZhang,ChunmeiXia,LiliZhu, Rui Wang, Jia Li, Hualiang Jiang, Zhenjiang Zhao*, Jing-Ya Li*, Honglin Li*. Discovery of a natural-product-derived preclinical candidate foronce-weekly treatment of type 2 diabetes. J. Med. Chem. 2019. 62(5): 2348-2361.（封面文章）
Shiliang Li#, Hongling Xu#, Shichao Cui#, Fangshu Wu#, Youli Zhang, Mingbo Su, Yinghui Gong, Shaobing Qiu, Qian Jiao, Chun Qin, Jiwei Shan, Ming Zhang, Jiawei Wang, Qiao Yin, Minghao Xu, Xiaofeng Liu, Rui Wang, Lili Zhu, Jia Li, Yufang Xu, Hualiang Jiang, Zhenjiang Zhao*, Jingya Li*, Honglin Li*. Discovery and rational design of natural product-derived 2-phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine analogs as novel and potent DPP-4 inhibitors for the treatment of type 2 diabetes. J. Med. Chem.2016, 59 (14), 6772-6790.
Yuan Yuan#, Junpeng Xu#, Lei Jiang#, Kangjie Yu#, Yuanyuan Ge, Mingyang Li, Huan He, Qiqi Niu, Xiayu Shi, Linni Fan, Zhuo Chen, Zhenjiang Zhao, Shiliang Li*, Yufang Xu*, Zhe Wang*, Honglin Li*. Discovery, optimization, and structure-activity relationship study of novel and potent RSK4 inhibitors as promising agents for the treatment of esophageal squamous cell carcinoma.J. Med. Chem. 2021. 64(18): 13572-13587.
Guixiang Yang, Songlan Ge, Yanwu, Jin Huang, Shiliang Li*, Rui Wang*, Lei Ma*. Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents. Eur. J. Med. Chem.2018, 156, 206-215.
Shiliang Li, Chaoqian Cai, Jiayu Gong, Xiaofeng Liu, Honglin Li*. A fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing. Proteins. 2021, 89(11): 1541-1556. （封面文章）
Disha Wang, Zihao Shen, Lei Jiang, Wenjun Liu, Jie Wang, Shiliang Li*, Honglin Li*. Deep learning based drug metabolites prediction. Front. Pharmacol. 2020. 10: 1586.
Shiliang li#, Yi Zhou#, Weiqiang Lu#, Ye Zhong, Jin Huang*, zhenjiang zhao, Xiaofeng Liu*, Yufang Xu, Honglin Li. Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-based Virtual Screening with the Inhibitor-constrained Refined Homology Model. J. Chem. Inf. Model. 2011. 51(11) : 2939-2947.
京公网安备 11010802027423号